Equities Analysts Offer Predictions for Tetraphase Pharmaceuticals Inc’s FY2017 Earnings (TTPH)

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) – B. Riley issued their FY2017 earnings per share (EPS) estimates for Tetraphase Pharmaceuticals in a note issued to investors on Monday. B. Riley analyst M. Kumar forecasts that the biopharmaceutical company will post earnings per share of ($2.70) for the year. B. Riley has a “Buy” rating and a $11.00 price objective on the stock. B. Riley also issued estimates for Tetraphase Pharmaceuticals’ FY2018 earnings at ($2.01) EPS.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. BidaskClub downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $14.46.

Shares of Tetraphase Pharmaceuticals (TTPH) opened at $5.43 on Wednesday. The company has a market cap of $265.71, a PE ratio of -1.90 and a beta of 2.29. Tetraphase Pharmaceuticals has a fifty-two week low of $4.91 and a fifty-two week high of $9.93.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in Tetraphase Pharmaceuticals during the third quarter worth approximately $107,000. Brighton Jones LLC acquired a new position in Tetraphase Pharmaceuticals during the third quarter worth approximately $108,000. Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in Tetraphase Pharmaceuticals during the second quarter worth approximately $147,000. Finally, Ameriprise Financial Inc. acquired a new position in Tetraphase Pharmaceuticals during the second quarter worth approximately $162,000. 58.28% of the stock is currently owned by institutional investors and hedge funds.

In other news, Director L Patrick Gage acquired 3,880 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the purchase, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The disclosure for this sale can be found here. 5.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: “Equities Analysts Offer Predictions for Tetraphase Pharmaceuticals Inc’s FY2017 Earnings (TTPH)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/02/14/equities-analysts-offer-predictions-for-tetraphase-pharmaceuticals-incs-fy2017-earnings-ttph.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply